| Year |
Citation |
Score |
| 2022 |
Hickman A, Koetsier J, Kurtanich T, Nielsen MC, Winn G, Wang Y, Bentebibel SE, Shi L, Punt S, Williams L, Haymaker C, Chesson CB, Fa'ak F, Dominguez A, Jones R, ... ... Hwu P, et al. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. The Journal of Clinical Investigation. PMID 35552271 DOI: 10.1172/JCI154152 |
0.325 |
|
| 2021 |
Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, ... ... Hwu P, et al. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. Journal For Immunotherapy of Cancer. 9. PMID 34021033 DOI: 10.1136/jitc-2021-002449 |
0.306 |
|
| 2021 |
Nave C, Roberts L, Hwu P, Estrella JD, Vo TC, Nguyen TH, Bui TT, Rindner DJ, Pervolarakis N, Shaw PJ, Leise TL, Holmes TC. Weekend light shifts evoke persistent Drosophila circadian neural network desynchrony. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33931552 DOI: 10.1523/JNEUROSCI.3074-19.2021 |
0.391 |
|
| 2020 |
Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, et al. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). Journal of Translational Medicine. 18: 346. PMID 32894202 DOI: 10.1186/S12967-020-02482-X |
0.306 |
|
| 2020 |
Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, et al. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discovery. PMID 32439653 DOI: 10.1158/2159-8290.CD-19-1510 |
0.313 |
|
| 2020 |
Saberian C, Amaria R, Haymaker C, Forget MA, Bassett R, Glitza I, Lizee G, Yee C, McQuade J, Wong M, Tawbi H, Patel S, Diab A, Davies M, Hwu P, et al. 311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma Journal For Immunotherapy of Cancer. 8: A338-A338. DOI: 10.1136/jitc-2020-sitc2020.0311 |
0.333 |
|
| 2020 |
Tsimberidou A, Guenther K, Alpert A, Andersson B, Coughlin Z, Fritsche J, Hilf N, Hwu P, Kalra M, Kuttruff-Coqui S, Maurer D, Mendrzyk R, Mohamed A, Norris B, Nowak A, et al. 293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101) Journal For Immunotherapy of Cancer. 8: A320-A320. DOI: 10.1136/jitc-2020-sitc2020.0293 |
0.311 |
|
| 2019 |
Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson H, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, ... ... Hwu P, et al. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8 T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31371342 DOI: 10.1158/1078-0432.Ccr-19-1259 |
0.316 |
|
| 2019 |
Ludford K, Johnson DH, Hennegan T, Gruschkus SK, Haymaker CL, Bernatchez C, Jackson N, Hwu P, Diab A. Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma. Journal of Clinical Oncology. 37: 9554-9554. DOI: 10.1200/JCO.2019.37.15_SUPPL.9554 |
0.333 |
|
| 2019 |
Mitra A, Andrews MC, Roh W, Macedo MPd, Reuben A, Carapeto F, Wang F, Reddy SM, Wani K, Spencer C, Miller J, Schalck A, Little LD, Sakellariou-Thompson DA, Gumbs C, ... ... Hwu P, et al. Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy Cancer Research. 79: 3776-3776. DOI: 10.1158/1538-7445.Sabcs18-3776 |
0.328 |
|
| 2019 |
Singh S, Bavisi K, Roszik J, Diab A, Davis RE, Hwu P, Overwijk WW, Singh M. Abstract 941: B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment Cancer Research. 79: 941-941. DOI: 10.1158/1538-7445.Am2019-941 |
0.305 |
|
| 2018 |
Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, ... ... Hwu P, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism. PMID 29628419 DOI: 10.1016/J.Cmet.2018.02.024 |
0.344 |
|
| 2018 |
Blumenschein GR, Bourgogne A, Reinhardt C, Ma H, Walter S, Weinschenk T, Kebriaei P, Hwu P, Singh H. Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC. Journal of Clinical Oncology. 36: TPS78-TPS78. DOI: 10.1200/JCO.2018.36.5_SUPPL.TPS78 |
0.342 |
|
| 2018 |
Tsimberidou AM, Stewart C, Reinhardt C, Ma H, Walter S, Weinschenk T, Jazaeri AA, Andersson B, Hwu P, Yee C, Singh H. Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers. Journal of Clinical Oncology. 36: TPS77-TPS77. DOI: 10.1200/JCO.2018.36.5_SUPPL.TPS77 |
0.324 |
|
| 2018 |
Sakellariou-Thompson D, Forget M, Roszik J, Jackson KR, Kim YU, Crosby S, Hurd MW, Wu J, Jiang Z, Hwu P, Lizee G, Menter D, Kopetz S, Overman MJ, Haymaker CL, et al. Preclinical development of tumor-infiltrating lymphocyte therapy for metastatic colorectal cancer. Journal of Clinical Oncology. 36: 95-95. DOI: 10.1200/Jco.2018.36.5_Suppl.95 |
0.336 |
|
| 2017 |
Forget M, Haymaker CL, Hess KR, Roszik J, Woodman SE, Fulbright OJ, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Amaria RN, Hwu P, Bernatchez C. The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center. Journal of Clinical Oncology. 35: 138-138. DOI: 10.1200/JCO.2017.35.7_SUPPL.138 |
0.312 |
|
| 2017 |
Hurwitz ME, Diab A, Bernatchez C, Haymaker CL, Kluger HM, Tetzlaff MT, Gergel I, Tagliaferri M, Imperiale M, Aung S, Hoch U, Zalevsky J, Hwu P, Sznol M, Tannir NM. Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 35: 454-454. DOI: 10.1200/Jco.2017.35.6_Suppl.454 |
0.323 |
|
| 2017 |
Keung E, Burton EM, Amaria RN, Glitza IC, Patel SP, Diab A, Yee C, Wong MK, Hwu W, Hwu P, Woodman SE, Tetzlaff MT, Milton D, Perez K, Davies MA, et al. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM). Journal of Clinical Oncology. 35: TPS9594-TPS9594. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS9594 |
0.328 |
|
| 2017 |
Diab A, Tannir NM, Bernatchez C, Haymaker CL, Bentebibel SE, Curti BD, Wong MK, Gergel I, Tagliaferri MA, Zalevsky J, Hoch U, Aung S, Imperiale M, Cho DC, Tykodi SS, ... ... Hwu P, et al. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. Journal of Clinical Oncology. 35: e14040-e14040. DOI: 10.1200/Jco.2017.35.15_Suppl.E14040 |
0.331 |
|
| 2017 |
Chen W, Andrews MC, Spencer C, Tawbi HA, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu W, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, et al. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). Journal of Clinical Oncology. 35: 9579-9579. DOI: 10.1200/Jco.2017.35.15_Suppl.9579 |
0.302 |
|
| 2017 |
Bernatchez C, Haymaker CL, Hurwitz ME, Kluger HM, Tetzlaff MT, Jackson N, Gergel I, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Iacucci E, Aung S, Imperiale M, Liao E, ... ... Hwu P, et al. Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. Journal of Clinical Oncology. 35: 2545-2545. DOI: 10.1200/Jco.2017.35.15_Suppl.2545 |
0.335 |
|
| 2016 |
McKenzie JA, Mbofung RM, Malu S, Hwu P. Abstract B152: Increasing the antitumor efficacy of immunotherapy in melanoma by using topoisomerase I inhibitors Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B152 |
0.345 |
|
| 2016 |
Williams L, Malu S, McKenzie J, Mbofung R, Roszik J, Hwu P. Abstract B118: Using a high throughput T-cell cytotoxicity assay to develop combination strategies for immunotherapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B118 |
0.303 |
|
| 2016 |
Mbofung RM, McKenzie JA, Malu S, Liu C, Peng W, Kuiatse I, Williams L, Devi S, Wang Z, Tieu T, Heffernan T, Davis RE, Amaria R, Hwu P. Abstract B105: HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B105 |
0.343 |
|
| 2016 |
Singh M, Vianden C, Diab A, Hwu P, Overwijk WW. Abstract B022: Intratumoral CD40 activation and checkpoint blockade induces systemic anti-melanoma immunity that eradicates disseminated tumors Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B022 |
0.318 |
|
| 2016 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, ... ... Hwu P, et al. Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Research. 76: 4363-4363. DOI: 10.1158/1538-7445.Am2016-4363 |
0.336 |
|
| 2016 |
Mbofung RM, McKenzie JA, Malu S, Liu C, Williams L, Peng W, Wang Z, Tripathi S, Tieu T, Zhao S, Devi S, Kuiatse I, Ashkin E, Bailey L, Roszik J, ... ... Hwu P, et al. Abstract 4360: Inhibition of HSP90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes Cancer Research. 76: 4360-4360. DOI: 10.1158/1538-7445.Am2016-4360 |
0.338 |
|
| 2016 |
McKenzie JA, Mbofung RM, Malu S, Amaria RN, Davis RE, Zhang L, Tieu TN, Heffernan TP, Hwu P. Abstract 4002: Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398 Cancer Research. 76: 4002-4002. DOI: 10.1158/1538-7445.Am2016-4002 |
0.34 |
|
| 2016 |
Wang Z, Malu S, Peng W, McKenzie J, Mbofung R, Williams L, Seth S, Heffernan T, Hwu P. Abstract 1441: Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens Cancer Research. 76: 1441-1441. DOI: 10.1158/1538-7445.Am2016-1441 |
0.307 |
|
| 2015 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, ... ... Hwu P, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.Cd-15-0283 |
0.313 |
|
| 2015 |
Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 112: 15408-13. PMID 26607445 DOI: 10.1073/Pnas.1512832112 |
0.311 |
|
| 2015 |
Martinez-Paniagua M, Haymaker C, Adolacion JR, Radvanyi L, Hwu P, Roysam B, Bernatchez C, Varadarajan N. Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P33 |
0.32 |
|
| 2013 |
Malu S, Mbofung R, Khalili J, Satani N, Forget M, Haymaker C, Muller F, Bernatchez C, Radvanyi L, Hwu P. Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity Journal For Immunotherapy of Cancer. 1: 164. DOI: 10.1186/2051-1426-1-S1-P164 |
0.32 |
|
| 2012 |
Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, ... ... Hwu P, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6758-70. PMID 23032743 DOI: 10.1158/1078-0432.Ccr-12-1177 |
0.324 |
|
| 2012 |
Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends in Immunology. 34: 90-8. PMID 23031830 DOI: 10.1016/j.it.2012.08.004 |
0.307 |
|
| 2012 |
Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 120: 4533-43. PMID 22936666 DOI: 10.1182/Blood-2012-02-407163 |
0.34 |
|
| 2012 |
Bernatchez C, Radvanyi LG, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Seminars in Oncology. 39: 215-26. PMID 22484193 DOI: 10.1053/j.seminoncol.2012.01.006 |
0.358 |
|
| 2012 |
Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer Journal (Sudbury, Mass.). 18: 160-75. PMID 22453018 DOI: 10.1097/PPO.0b013e31824d4465 |
0.32 |
|
| 2011 |
Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1664-73. PMID 21325070 DOI: 10.1158/1078-0432.CCR-10-2272 |
0.322 |
|
| 2007 |
Lizee GA, Cantu MA, Hwu P. Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy Clinical Cancer Research. 13: 5250-5255. PMID 17875752 DOI: 10.1158/1078-0432.Ccr-07-1722 |
0.342 |
|
| 2006 |
Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5801-8. PMID 17020987 DOI: 10.1158/1078-0432.Ccr-05-2421 |
0.302 |
|
| 2006 |
Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4794-803. PMID 16914564 DOI: 10.1158/1078-0432.Ccr-06-0944 |
0.316 |
|
| 2006 |
Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2359s-2365s. PMID 16609059 DOI: 10.1158/1078-0432.Ccr-05-2537 |
0.324 |
|
| 2003 |
Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 385-93. PMID 12973027 DOI: 10.1097/00002371-200309000-00001 |
0.324 |
|
| 2002 |
Toso JF, Lapointe R, Hwu P. CD40 ligand and lipopolysaccharide enhance the in vitro generation of melanoma-reactive T-cells Journal of Immunological Methods. 259: 181-190. PMID 11730853 DOI: 10.1016/S0022-1759(01)00513-0 |
0.32 |
|
| Show low-probability matches. |